SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 208 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $328,323 | -90.6% | 202,674 | -45.2% | 0.00% | -93.9% |
| Q3 2020 | $3,496,000 | +5.5% | 370,000 | 0.0% | 0.03% | -5.7% |
| Q2 2020 | $3,315,000 | -22.1% | 370,000 | -28.8% | 0.04% | -25.5% |
| Q1 2020 | $4,255,000 | -2.2% | 520,000 | 0.0% | 0.05% | 0.0% |
| Q4 2019 | $4,352,000 | -21.8% | 520,000 | -15.4% | 0.05% | -36.5% |
| Q3 2019 | $5,566,000 | +25.1% | 615,000 | +48.2% | 0.07% | +32.1% |
| Q2 2019 | $4,450,000 | +216.1% | 415,000 | +159.4% | 0.06% | +115.4% |
| Q2 2017 | $1,408,000 | +0.3% | 160,000 | -40.7% | 0.03% | -3.7% |
| Q1 2017 | $1,404,000 | +130.2% | 270,000 | +35.0% | 0.03% | +92.9% |
| Q4 2016 | $610,000 | -34.1% | 200,000 | 0.0% | 0.01% | -36.4% |
| Q3 2016 | $926,000 | -20.0% | 200,000 | 0.0% | 0.02% | -26.7% |
| Q2 2016 | $1,158,000 | -3.7% | 200,000 | 0.0% | 0.03% | 0.0% |
| Q1 2016 | $1,203,000 | -34.1% | 200,000 | +66.7% | 0.03% | -21.1% |
| Q4 2014 | $1,825,000 | – | 120,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |